SecBot SecBot
SECBOTREPLAY Home › Report › DNTH

DNTH · Dianthus Therapeutics posted an updated corporate presentation…

Dianthus Therapeutics, Inc. /DE/ · 8-K filed Jun 12, 2026 at 07:00 ET

At the news

BULLISHIMPACT 7/10

8-K filed Jun 12, 2026 at 07:00 ET

Dianthus Therapeutics posted an updated corporate presentation disclosing a 75% confirmed responder rate from the first 40 patients completing Part A of the Phase 3 CAPTIVATE trial of claseprubart in CIDP. The data supports an early GO decision and a streamlined trial design with ~1/3 fewer Part B patients, with Part B top-line guidance expected by YE'26. The filing also reiterates upcoming catalysts: Ph. 3 gMG EMERGE initiation (mid-'26), Ph. 2 MMN MoMeNtum data (Q4'26), and Ph. 1 DNTH212 data (2H'26).

  • 75% confirmed responder rate (30 of 40) in Part A of CAPTIVATE Ph. 3 CIDP trial, exceeding the 50% threshold for GO decision
  • CAPTIVATE trial design streamlined: Part B reduced from 192 to 128 patients, Part A enrollment capped at 256 vs. 480
  • No related serious infections, no clinical symptoms of DIL, no related SAEs or discontinuations in interim analysis
  • Cash position of ~$1.2B as of March 31, 2026, with runway into 2030

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access